Poster: AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies

This integrated analysis is the largest collation of safety data following treatment with TAG monotherapy. Most TRAEs were transient, and their frequency/severity decreased with increasing cycles. No myelosuppression or cumulative toxicity was reported following treatment over multiple cycles. These data confirm that the established and manageable safety profile of TAG monotherapy has been maintained in the 3 years following US approval.